Malignant Diseases of The Lung: Incidence and Screening of Non Small Cell Lung Cancer

Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.

Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3:819–831.

Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest.2003;123(1 suppl):21S-49S.

Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. LancetOncol. 2005;6(10):773-779.

Huang YJ, Huang TW, Lin FH, Chung CH, Tsao CH, Chien WC.Radiation therapy for invasive breast cancer increases the risk ofsecond primary lung cancer: a nationwide population-basedcohort analysis. J Thorac Oncol. 2017;12(5):782-790.

Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study.Am J Respir Crit Care Med. 2000;161(1):5-8.

Kirk GD, Merlo C, O’ Driscoll P, et al. HIV infection is associatedwith an increased risk for lung cancer, independent ofsmoking. Clin Infect Dis. 2007;45(1):103-110.

Sartorius B, Sartorius K. How much incident lung cancer was missed globally in 2012? An ecological country-level study.Geospat Health. 2016;11(2):396.

Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-644.

Kohler BA, Ward E, McCarthy BJ, et al. Annual report to thenation on the status of cancer, 1975-2007, featuring tumors ofthe brain and other nervous systems. J Natl Cancer Inst. 2011;103(9):714-736.

Lung cancer incidence in never-smokers; J Clin Oncol. 2007 February 10; 25(5): 472 478. DOI:10.1200/JCO.2006.07.2983.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA CancerJ Clin. 2018;68(1):7 30.

1. NCI: SEER Cancer Statistics Review; 1996-2002.

Goldstraw P, Crowley J, Chansky K, GirouxDJ, Groome PA, Rami-Porta R, et al. TheIASLC Lung Cancer Staging Project: proposalsfor the revision of the TNM stage groupingsin the forthcoming (seventh) edition of theTNM classification of malignant tumors. JThorac Oncol 2007;2:706-14.

Felten MK, Knoll L, Schikowsky C. Is it useful to combine sputum cytology and low-dose spiral computed tomography for early detection of lung cancer in formerly asbestos-exposed power industry workers? Journal of Occupational Medicine and Toxicology. 2014. 9:14. DOI:10.1186/1745-6673-9-14

Kaneko M, Eguchi K, Ohmatsu H, KakinumaR, Naruke T, Suemasu K, et al. Peripherallung cancer: screening and detection with low-dosespiral CT versus radiography. Radiology1996;201(3):798-802.

International Early Lung Cancer Action ProgramInvestigators, Henschke CI, YankelevitzDF, Libby DM, Pasmantier MW, Smith JP, MiettinenOS. Survival of patients with stage Ilung cancer detected on CT screening. N EnglJ Med 2006;355(17):1763-71.

Aberle DR, Adams AM, Berg CD, Black WC,Clapp JD, Fagerstrom RM, et al. NationalLung Screening Trial Research Team. Reducedlung-cancer mortality with low-dosecomputed tomographic screening. N Engl JMed 2011;365:395-409.

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, Food and Drug Administration, 2016.

Boyle P, Chapman CJ, Holdenrieder S, MurrayA, Robertson C, Wood WC, et al. Clinicalvalidation of an autoantibody test for lung cancer.Ann Oncol 2011;22(2):383-9.

Ma S, Wang W, Xia B, Zhang S, Yuan H,Jiang H, et al. Multiplexed serum biomarkers for the detection of lung cancer. Biomedicine2016;11:210-8.

Alipoor SD, Adcock IM, Garssen J, Mortaz E,Varahram M, Mirsaeidi M, et al. The roles ofmiRNAs as potential biomarkers in lung diseases.Eur J Pharmacol 2016;791:395-404.

H. J. O'Neill, S. M. Gordon, M. H. O'Neill, R. D. Gibbons, and J. P. Szidon, “A computerized classification technique for screening for the presence of breath biomarkers in lung cancer,” Clinical Chemistry, vol. 34, no. 8, pp. 1613–1618, 1988.View at: Google Scholar

B. Ibrahim, M. Basanta, P. Cadden et al., “Non-invasive phenotyping using exhaled volatile organic compounds in asthma,” Thorax, vol. 66, no. 9, pp. 804–809, 2011.View at: Publisher Site | Google Scholar

M. Barker, M. Hengst, J. Schmid et al., “Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis,” European Respiratory Journal, vol. 27, no. 5, pp. 929–936, 2006.View at: Publisher Site | Google Scholar

M. Phillips, R. N. Cataneo, T. Cheema, and J. Greenberg, “Increased breath biomarkers of oxidative stress in diabetes mellitus,” Clinica Chimica Acta, vol. 344, no. 1-2, pp. 189–194, 2004.View at: Publisher Site | Google Scholar

M. Phillips, R. N. Cataneo, R. Condos et al., “Volatile biomarkers of pulmonary tuberculosis in the breath,” Tuberculosis, vol. 87, no. 1, pp. 44–52, 2007.View at: Publisher Site | Google Scholar

C. O. Phillips, Y. Syed, N. M. Parthaláin, R. Zwiggelaar, T. C. Claypole, and K. E. Lewis, “Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls,” Journal of Breath Research, vol. 6, no. 3, Article ID 036003, 2012.View at: Publisher Site | Google Scholar

M. Phillips, J. P. Boehmer, R. N. Cataneo, et al., “Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study),” Journal of Heart and Lung Transplantation, vol. 23, no. 6, pp. 701–708, 2004.View at: Publisher Site | Google Scholar

I. Ahmed, R. Greenwood, B. de Lacy Costello, N. M. Ratcliffe, and C. S. Probert, “An investigation of fecal volatile organic metabolites in irritable bowel syndrome,” PLoS ONE, vol. 8, no. 3, Article ID e58204, 2013.View at Publisher Site | Google Scholar

Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon; Eur Respir J 2012; 39: 669–676 DOI: 10.1183/09031936.00051711